Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Rodríguez de Córdoba S[au]:

Search results

Items: 1 to 50 of 160

1.

Preface.

Rodríguez de Córdoba S.

Mol Immunol. 2019 Oct;114:312-313. doi: 10.1016/j.molimm.2019.08.009. Epub 2019 Aug 20. No abstract available.

PMID:
31442914
2.

Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.

Cavero T, Arjona E, Soto K, Caravaca-Fontán F, Rabasco C, Bravo L, de la Cerda F, Martín N, Blasco M, Ávila A, Huerta A, Cabello V, Jarque A, Alcázar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, Iglesias E, Baltar J, Martínez-Gallardo R, Pérez L, Morales E, González R, Macía M, Draibe J, Pallardó L, Quintana LF, Espinosa M, Barros X, Pereira F, Cao M, Moreno JA, Rodríguez de Córdoba S, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN).

Kidney Int. 2019 Oct;96(4):995-1004. doi: 10.1016/j.kint.2019.05.014. Epub 2019 May 31.

PMID:
31420192
3.

Secondary atypical hemolytic uremic syndromes in the era of complement blockade.

Praga M, Rodríguez de Córdoba S.

Kidney Int. 2019 Jun;95(6):1298-1300. doi: 10.1016/j.kint.2019.01.043.

PMID:
31122707
4.

The Antimicrobials Anacardic Acid and Curcumin Are Not-Competitive Inhibitors of Gram-Positive Bacterial Pathogenic Glyceraldehyde-3-Phosphate Dehydrogenase by a Mechanism Unrelated to Human C5a Anaphylatoxin Binding.

Gómez S, Querol-García J, Sánchez-Barrón G, Subias M, González-Alsina À, Franco-Hidalgo V, Albertí S, Rodríguez de Córdoba S, Fernández FJ, Vega MC.

Front Microbiol. 2019 Feb 26;10:326. doi: 10.3389/fmicb.2019.00326. eCollection 2019.

5.

Kidney, hypertension and complement activation. In search of new therapeutic targets.

Rodríguez de Córdoba S, Espinosa Hernández M.

Nefrologia. 2019 Mar - Apr;39(2):111-114. doi: 10.1016/j.nefro.2018.10.002. Epub 2018 Dec 7. English, Spanish. No abstract available.

6.

Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.

Cao M, Leite BN, Ferreiro T, Calvo M, Fernández C, Alonso Á, Rodriguez A, Salvador P, Seijo R, Pita S, Arjona E, Rodríguez de Córdoba S, Valdés Cañedo F.

Am J Nephrol. 2018;48(3):225-233. doi: 10.1159/000492865. Epub 2018 Sep 11.

PMID:
30205388
7.

Common and rare genetic variants of complement components in human disease.

Goicoechea de Jorge E, López Lera A, Bayarri-Olmos R, Yebenes H, Lopez-Trascasa M, Rodríguez de Córdoba S.

Mol Immunol. 2018 Oct;102:42-57. doi: 10.1016/j.molimm.2018.06.011. Epub 2018 Jun 18. Review.

PMID:
29914697
8.

High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele CFHR3*B.

Pouw RB, Gómez Delgado I, López Lera A, Rodríguez de Córdoba S, Wouters D, Kuijpers TW, Sánchez-Corral P.

Front Immunol. 2018 Apr 24;9:848. doi: 10.3389/fimmu.2018.00848. eCollection 2018.

9.

Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Osborne AJ, Breno M, Borsa NG, Bu F, Frémeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodríguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ.

J Immunol. 2018 Apr 1;200(7):2464-2478. doi: 10.4049/jimmunol.1701695. Epub 2018 Mar 2.

10.

Absence of CD59 in Guinea Pigs: Analysis of the Cavia porcellus Genome Suggests the Evolution of a CD59 Pseudogene.

Boshra H, Zelek WM, Hughes TR, Rodriguez de Cordoba S, Morgan BP.

J Immunol. 2018 Jan 1;200(1):327-335. doi: 10.4049/jimmunol.1701238. Epub 2017 Nov 22.

11.

Human plasma C3 is essential for the development of memory B, but not T, lymphocytes.

Jiménez-Reinoso A, Marin AV, Subias M, López-Lera A, Román-Ortiz E, Payne K, Ma CS, Arbore G, Kolev M, Freeley SJ, Kemper C, Tangye SG, Fernández-Malavé E, Rodríguez de Córdoba S, López-Trascasa M, Regueiro JR.

J Allergy Clin Immunol. 2018 Mar;141(3):1151-1154.e14. doi: 10.1016/j.jaci.2017.09.037. Epub 2017 Nov 4. No abstract available.

PMID:
29113906
12.

Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome.

Goicoechea de Jorge E, Tortajada A, García SP, Gastoldi S, Merinero HM, García-Fernández J, Arjona E, Cao M, Remuzzi G, Noris M, Rodríguez de Córdoba S.

J Am Soc Nephrol. 2018 Jan;29(1):240-249. doi: 10.1681/ASN.2017050518. Epub 2017 Oct 9.

13.

Complete functional characterization of disease-associated genetic variants in the complement factor H gene.

Merinero HM, García SP, García-Fernández J, Arjona E, Tortajada A, Rodríguez de Córdoba S.

Kidney Int. 2018 Feb;93(2):470-481. doi: 10.1016/j.kint.2017.07.015. Epub 2017 Sep 21.

PMID:
28941939
14.

A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.

Huerta A, Arjona E, Portoles J, Lopez-Sanchez P, Rabasco C, Espinosa M, Cavero T, Blasco M, Cao M, Manrique J, Cabello-Chavez V, Suñer M, Heras M, Fulladosa X, Belmar L, Sempere A, Peralta C, Castillo L, Arnau A, Praga M, Rodriguez de Cordoba S.

Kidney Int. 2018 Feb;93(2):450-459. doi: 10.1016/j.kint.2017.06.022. Epub 2017 Sep 12.

PMID:
28911789
15.

Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy.

Tortajada A, Gutiérrez E, Goicoechea de Jorge E, Anter J, Segarra A, Espinosa M, Blasco M, Roman E, Marco H, Quintana LF, Gutiérrez J, Pinto S, Lopez-Trascasa M, Praga M, Rodriguez de Córdoba S.

Kidney Int. 2017 Oct;92(4):953-963. doi: 10.1016/j.kint.2017.03.041. Epub 2017 Jun 19.

PMID:
28637589
16.

Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.

Nitschke F, Sullivan MA, Wang P, Zhao X, Chown EE, Perri AM, Israelian L, Juana-López L, Bovolenta P, Rodríguez de Córdoba S, Steup M, Minassian BA.

EMBO Mol Med. 2017 Jul;9(7):906-917. doi: 10.15252/emmm.201707608.

17.

FHR-1 Binds to C-Reactive Protein and Enhances Rather than Inhibits Complement Activation.

Csincsi ÁI, Szabó Z, Bánlaki Z, Uzonyi B, Cserhalmi M, Kárpáti É, Tortajada A, Caesar JJE, Prohászka Z, Jokiranta TS, Lea SM, Rodríguez de Córdoba S, Józsi M.

J Immunol. 2017 Jul 1;199(1):292-303. doi: 10.4049/jimmunol.1600483. Epub 2017 May 22.

18.

Crystal Structure of Glyceraldehyde-3-Phosphate Dehydrogenase from the Gram-Positive Bacterial Pathogen A. vaginae, an Immunoevasive Factor that Interacts with the Human C5a Anaphylatoxin.

Querol-García J, Fernández FJ, Marin AV, Gómez S, Fullà D, Melchor-Tafur C, Franco-Hidalgo V, Albertí S, Juanhuix J, Rodríguez de Córdoba S, Regueiro JR, Vega MC.

Front Microbiol. 2017 Apr 10;8:541. doi: 10.3389/fmicb.2017.00541. eCollection 2017.

19.

Eculizumab in secondary atypical haemolytic uraemic syndrome.

Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, García A, Mendizabal S, Gavela E, Macía M, Quintana LF, María Romera A, Borrego J, Arjona E, Espinosa M, Portolés J, Gracia-Iguacel C, González-Parra E, Aljama P, Morales E, Cao M, Rodríguez de Córdoba S, Praga M.

Nephrol Dial Transplant. 2017 Mar 1;32(3):466-474. doi: 10.1093/ndt/gfw453.

20.

Ionic tethering contributes to the conformational stability and function of complement C3b.

López-Perrote A, Harrison RE, Subías M, Alcorlo M, Rodríguez de Córdoba S, Morikis D, Llorca O.

Mol Immunol. 2017 May;85:137-147. doi: 10.1016/j.molimm.2016.12.015. Epub 2017 Mar 8.

PMID:
28254726
21.

Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.

Subías Hidalgo M, Yébenes H, Rodríguez-Gallego C, Martín-Ambrosio A, Domínguez M, Tortajada A, Rodríguez de Córdoba S, Llorca O.

Eur J Immunol. 2017 Mar;47(3):504-515. doi: 10.1002/eji.201646758. Epub 2017 Feb 6.

22.

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants.

Kidney Int. 2017 Mar;91(3):539-551. doi: 10.1016/j.kint.2016.10.005. Epub 2016 Dec 16.

23.

Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.

Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S.

Clin Adv Hematol Oncol. 2016 Nov;14 Suppl 11(11):2-15. Review.

PMID:
27930620
24.

Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.

Subías Hidalgo M, Martin Merinero H, López A, Anter J, García SP, Ataúlfo Gonzalez-Fernández F, Forés R, Lopez-Trascasa M, Villegas A, Ojeda E, Rodríguez de Córdoba S.

Immunobiology. 2017 Feb;222(2):363-371. doi: 10.1016/j.imbio.2016.09.002. Epub 2016 Sep 13.

25.

Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.

Blom AM, Corvillo F, Magda M, Stasiłojć G, Nozal P, Pérez-Valdivia MÁ, Cabello-Chaves V, Rodríguez de Córdoba S, López-Trascasa M, Okrój M.

J Clin Immunol. 2016 Jul;36(5):517-27. doi: 10.1007/s10875-016-0290-5. Epub 2016 May 5.

26.

The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in Monocyte-Derived Dendritic Cells.

Olivar R, Luque A, Cárdenas-Brito S, Naranjo-Gómez M, Blom AM, Borràs FE, Rodriguez de Córdoba S, Zipfel PF, Aran JM.

J Immunol. 2016 May 15;196(10):4274-90. doi: 10.4049/jimmunol.1500455. Epub 2016 Apr 13.

27.

Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.

Corvillo F, Bravo García-Morato M, Nozal P, Garrido S, Tortajada A, Rodríguez de Córdoba S, López-Trascasa M.

Clin Exp Immunol. 2016 Apr;184(1):118-25. doi: 10.1111/cei.12754. Epub 2016 Jan 22.

28.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.

Nefrologia. 2015;35(5):421-47. doi: 10.1016/j.nefro.2015.07.005. Epub 2015 Oct 9. English, Spanish.

29.

Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases.

Recalde S, Tortajada A, Subias M, Anter J, Blasco M, Maranta R, Coco R, Pinto S, Noris M, García-Layana A, Rodríguez de Córdoba S.

J Am Soc Nephrol. 2016 May;27(5):1305-11. doi: 10.1681/ASN.2015050580. Epub 2015 Sep 16.

30.

Structural insights on complement activation.

Alcorlo M, López-Perrote A, Delgado S, Yébenes H, Subías M, Rodríguez-Gallego C, Rodríguez de Córdoba S, Llorca O.

FEBS J. 2015 Oct;282(20):3883-91. doi: 10.1111/febs.13399. Epub 2015 Aug 31. Review.

31.

Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.

Bernabéu-Herrero ME, Jiménez-Alcázar M, Anter J, Pinto S, Sánchez Chinchilla D, Garrido S, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P.

Mol Immunol. 2015 Oct;67(2 Pt B):276-86. doi: 10.1016/j.molimm.2015.06.021. Epub 2015 Jul 7.

PMID:
26163426
32.

Factor H-related proteins determine complement-activating surfaces.

Józsi M, Tortajada A, Uzonyi B, Goicoechea de Jorge E, Rodríguez de Córdoba S.

Trends Immunol. 2015 Jun;36(6):374-84. doi: 10.1016/j.it.2015.04.008. Epub 2015 May 13. Review.

PMID:
25979655
33.

The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome.

Martínez-Barricarte R, Heurich M, López-Perrote A, Tortajada A, Pinto S, López-Trascasa M, Sánchez-Corral P, Morgan BP, Llorca O, Harris CL, Rodríguez de Córdoba S.

Mol Immunol. 2015 Aug;66(2):263-73. doi: 10.1016/j.molimm.2015.03.248. Epub 2015 Apr 11.

34.

[Atypical hemolytic uremic syndrome].

Blasco Pelicano M, Rodríguez de Córdoba S, Campistol Plana JM.

Med Clin (Barc). 2015 Nov 20;145(10):438-45. doi: 10.1016/j.medcli.2014.08.006. Epub 2014 Nov 26. Review. Spanish.

35.

Pleiotropic effects of cell wall amidase LytA on Streptococcus pneumoniae sensitivity to the host immune response.

Ramos-Sevillano E, Urzainqui A, Campuzano S, Moscoso M, González-Camacho F, Domenech M, Rodríguez de Córdoba S, Sánchez-Madrid F, Brown JS, García E, Yuste J.

Infect Immun. 2015 Feb;83(2):591-603. doi: 10.1128/IAI.02811-14. Epub 2014 Nov 17.

36.

A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.

Subías M, Tortajada A, Gastoldi S, Galbusera M, López-Perrote A, Lopez Lde J, González-Fernández FA, Villegas-Martínez A, Dominguez M, Llorca O, Noris M, Morgan BP, Rodríguez de Córdoba S.

J Immunol. 2014 Dec 1;193(11):5567-75. doi: 10.4049/jimmunol.1402013. Epub 2014 Oct 29.

37.

Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome.

Sánchez Chinchilla D, Pinto S, Hoppe B, Adragna M, Lopez L, Justa Roldan ML, Peña A, Lopez Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S.

Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1611-9. doi: 10.2215/CJN.01640214. Epub 2014 Aug 18.

38.

Eculizumab in dense-deposit disease after renal transplantation.

Sánchez-Moreno A, De la Cerda F, Cabrera R, Fijo J, López-Trascasa M, Bedoya R, Rodríguez de Córdoba S, Ybot-González P.

Pediatr Nephrol. 2014 Oct;29(10):2055-9. doi: 10.1007/s00467-014-2839-y. Epub 2014 Jun 8.

PMID:
24908321
39.

A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.

Valoti E, Alberti M, Tortajada A, Garcia-Fernandez J, Gastoldi S, Besso L, Bresin E, Remuzzi G, Rodriguez de Cordoba S, Noris M.

J Am Soc Nephrol. 2015 Jan;26(1):209-19. doi: 10.1681/ASN.2013121339. Epub 2014 Jun 5.

40.

Genetics of atypical hemolytic uremic syndrome (aHUS).

Rodríguez de Córdoba S, Hidalgo MS, Pinto S, Tortajada A.

Semin Thromb Hemost. 2014 Jun;40(4):422-30. doi: 10.1055/s-0034-1375296. Epub 2014 May 5. Review.

PMID:
24799305
41.

A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors.

Paixão-Cavalcante D, Torreira E, Lindorfer MA, Rodriguez de Cordoba S, Morgan BP, Taylor RP, Llorca O, Harris CL.

J Immunol. 2014 May 15;192(10):4844-51. doi: 10.4049/jimmunol.1303131. Epub 2014 Apr 11.

42.

The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease.

Gayarre J, Duran-Trío L, Criado Garcia O, Aguado C, Juana-López L, Crespo I, Knecht E, Bovolenta P, Rodríguez de Córdoba S.

Brain. 2014 Mar;137(Pt 3):806-18. doi: 10.1093/brain/awt353. Epub 2014 Jan 14.

43.

Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.

Liszewski MK, Kolev M, Le Friec G, Leung M, Bertram PG, Fara AF, Subias M, Pickering MC, Drouet C, Meri S, Arstila TP, Pekkarinen PT, Ma M, Cope A, Reinheckel T, Rodriguez de Cordoba S, Afzali B, Atkinson JP, Kemper C.

Immunity. 2013 Dec 12;39(6):1143-57. doi: 10.1016/j.immuni.2013.10.018. Epub 2013 Dec 5.

44.

C3 glomerulopathy: consensus report.

Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT.

Kidney Int. 2013 Dec;84(6):1079-89. doi: 10.1038/ki.2013.377. Epub 2013 Oct 30.

45.

Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene.

Román-Ortiz E, Mendizabal Oteiza S, Pinto S, López-Trascasa M, Sánchez-Corral P, Rodríguez de Cordoba S.

Pediatr Nephrol. 2014 Jan;29(1):149-53. doi: 10.1007/s00467-013-2591-8. Epub 2013 Aug 24.

PMID:
23982707
46.

Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.

Alcorlo M, Tortajada A, Rodríguez de Córdoba S, Llorca O.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13504-9. doi: 10.1073/pnas.1309618110. Epub 2013 Jul 30.

47.

C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.

Tortajada A, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, Alba-Domínguez M, Malik TH, Bedoya R, Cabrera Pérez R, López Trascasa M, Pickering MC, Harris CL, Sánchez-Corral P, Llorca O, Rodríguez de Córdoba S.

J Clin Invest. 2013 Jun;123(6):2434-46.

48.

Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M; European Working Party on Complement Genetics in Renal Diseases.

J Am Soc Nephrol. 2013 Feb;24(3):475-86. doi: 10.1681/ASN.2012090884. Epub 2013 Feb 21.

49.

The α7β0 isoform of the complement regulator C4b-binding protein induces a semimature, anti-inflammatory state in dendritic cells.

Olivar R, Luque A, Naranjo-Gómez M, Quer J, García de Frutos P, Borràs FE, Rodríguez de Córdoba S, Blom AM, Aran JM.

J Immunol. 2013 Mar 15;190(6):2857-72. doi: 10.4049/jimmunol.1200503. Epub 2013 Feb 6.

50.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyó JM, Praga M, Torra R, Vilalta R, Rodríguez de Córdoba S.

Nefrologia. 2013 Jan 18;33(1):27-45. doi: 10.3265/Nefrologia.pre2012.Nov.11781. English, Spanish.

Supplemental Content

Loading ...
Support Center